-
The application for the listing of regenerant biology Terripley single anti-new anti-adhesive disease was accepted
Time of Update: 2021-03-07
On February 18, Junshi Bio announced that the company had received a "notice of acceptance" approved by the State Drug Administration, and that the new adaptation application for Ripley monoantithermal combination chemotherapy for advanced first-line
-
Dongguan Tangxia Town standard wooden furniture enterprises prevention and control of occupational diseases
Time of Update: 2021-03-07
Using one year's management time, the wooden furniture manufacturing enterprises are required to complete the transformation of occupational hazard management and protective facilities.
-
Slow-disease diagnosis and treatment company Shuo Mao Technology completed tens of millions of strategic financing
Time of Update: 2021-03-06
is understood to have completed tens of millions of strategic financings from Schomau Technology, a slow-motion healthcare company, funded by Aptar, the world's leading provider of packaging solutions for the healthcare and consumer
-
Nano Today: Scientists have developed a new type of artificial nanoenzyme that promises to treat Parkinson's disease
Time of Update: 2021-03-06
lumpy structures - Lewy bodies, which can cause brain cell death as these lumpy structures accumulate. , in a study published in the international journal Nano Today, scientists from Johns Hopkins University School of Medicine and others
-
Sci Adv: What's new! The metabolic defects of the Parkinson's disease drug L-Doba are directly related to severe side effects in the patient's body!
Time of Update: 2021-03-06
January 11, 2021 // -- So far, researchers don't know why the drug levodopa (L-Dopa), which can reduce motor symptoms in people with Parkinson's disease, is declining after several years of use; One of the most common side effects is that patients
-
Sci Adv: Develops new methods that promise to study the pathogenesis of a variety of autoimmune diseases
Time of Update: 2021-03-06
January 12, 2021 // -- Scientists from the Indiana Institute of Biological Sciences and others have found that identifying new treatments for autoimmune diseases may require research into the immune system and their target tissues, according
-
receives FDA Priority Review: Significantly Extending Disease-Free Survival!
Time of Update: 2021-03-06
) and a centralized review process has been initiated. application is based on the results of Phase 3 CheckMate-577 trials. data show that opdivo-assisted therapy doubled the patient's disease-free survival (DFS) (median DFS: 22.4 months vs
-
Neurology: People who eat foods rich in vitamin C and E may have a one-third lower risk of Parkinson's disease!
Time of Update: 2021-03-06
January 12, 2021 // -- In a recent study published in the international journal Newology, researchers from abroad found that people who ate foods rich in vitamin C and vitamin E may have a reduced risk of Parkinson's disease by nearly a third.
-
New anti-inflammatory drugs! AbbVie IL-23 inhibitor Skyrizi's treatment of Crohn's disease (CD) 2 Phase III induction studies have been successful!
Time of Update: 2021-03-06
, clinical remission was measured by CDAI (Crohn's Disease Activity Index) and PRO-2 (two-part patient reporting results). in the ADVANCE study, there was a significant increase in the proportion of patients treated with 600 mg or 1200 mg Skyrizi
-
JBC: Key proteins prevent Alzheimer's disease
Time of Update: 2021-03-06
However, when they are separated into molecules called monobodies, these individual fragments can function like amyloid β, forming viscous primary fibers that combine to form toxic clumps in the heart and nerves, causing rare amyloid degeneration.
-
Recent interpretation of important research findings in the field of Parkinson's disease research!
Time of Update: 2021-03-05
